185 related articles for article (PubMed ID: 9412812)
41. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas.
Cordon-Cardo C; Latres E; Drobnjak M; Oliva MR; Pollack D; Woodruff JM; Marechal V; Chen J; Brennan MF; Levine AJ
Cancer Res; 1994 Feb; 54(3):794-9. PubMed ID: 8306343
[TBL] [Abstract][Full Text] [Related]
42. Immunohistochemical detection of p53 protein overexpression versus gene sequencing in urinary bladder carcinomas.
Bernardini S; Adessi GL; Billerey C; Chezy E; Carbillet JP; Bittard H
J Urol; 1999 Oct; 162(4):1496-501. PubMed ID: 10492244
[TBL] [Abstract][Full Text] [Related]
43. [Alterations of MDM2 and p53 genes in bone tumors].
Zhou X; Gao L; Zhe X
Zhonghua Bing Li Xue Za Zhi; 1997 Oct; 26(5):270-2. PubMed ID: 10374333
[TBL] [Abstract][Full Text] [Related]
44. p16INK4A is regularly expressed in Hodgkin's disease: comparison with retinoblastoma, p53 and MDM2 protein status, and the presence of Epstein-Barr virus.
Guenova M; Rassidakis GZ; Gorgoulis VG; Angelopoulou MK; Siakantaris MR; Kanavaros P; Pangalis GA; Kittas C
Mod Pathol; 1999 Nov; 12(11):1062-71. PubMed ID: 10574604
[TBL] [Abstract][Full Text] [Related]
45. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein.
Landers JE; Cassel SL; George DL
Cancer Res; 1997 Aug; 57(16):3562-8. PubMed ID: 9270029
[TBL] [Abstract][Full Text] [Related]
46. Aberrant expression of the cell cycle associated proteins TP53, MDM2, p21, p27, cdk4, cyclin D1, RB, and EGFR in cervical carcinomas.
Skomedal H; Kristensen GB; Lie AK; Holm R
Gynecol Oncol; 1999 May; 73(2):223-8. PubMed ID: 10329038
[TBL] [Abstract][Full Text] [Related]
47. [Interaction between p53 and MDM2 in human lung cancer cells].
Rybárová S; Hodorová I; Vecanová J; Muri J; Mihalik J
Klin Onkol; 2014; 27(1):33-7. PubMed ID: 24635435
[TBL] [Abstract][Full Text] [Related]
48. Nuclear accumulation of MDM2 protein in well-differentiated papillary thyroid carcinomas.
Jennings T; Bratslavsky G; Gerasimov G; Troshina K; Bronstein M; Dedov I; Alexandrova G; Figge J
Exp Mol Pathol; 1995 Jun; 62(3):199-206. PubMed ID: 8612724
[TBL] [Abstract][Full Text] [Related]
49. Human bladder carcinoma cell lines as indicators of oncogenic change relevant to urothelial neoplastic progression.
Rieger KM; Little AF; Swart JM; Kastrinakis WV; Fitzgerald JM; Hess DT; Libertino JA; Summerhayes IC
Br J Cancer; 1995 Sep; 72(3):683-90. PubMed ID: 7669581
[TBL] [Abstract][Full Text] [Related]
50. MDM2/p53 co-expression in oral premalignant and malignant lesions: potential prognostic implications.
Agarwal S; Mathur M; Srivastava A; Ralhan R
Oral Oncol; 1999 Mar; 35(2):209-16. PubMed ID: 10435158
[TBL] [Abstract][Full Text] [Related]
51. Expression of mdm-2 and p53 protein in transitional cell carcinoma.
Barbareschi M; Girlando S; Fellin G; Graffer U; Luciani L; Dalla Palma P
Urol Res; 1995; 22(6):349-52. PubMed ID: 7537927
[TBL] [Abstract][Full Text] [Related]
52. p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder.
Casetta G; Gontero P; Russo R; Pacchioni D; Tizzani A
Eur Urol; 1997; 32(2):229-36. PubMed ID: 9286659
[TBL] [Abstract][Full Text] [Related]
53. [TP53 gene aberrations in chondromatous neoplasms: correlation with immunohistochemical p53 accumulation and MDM2 expression].
Blasenbreu S; Baretton GB; Bender C; Haas CJ; Diebold J; Löhrs U
Verh Dtsch Ges Pathol; 1998; 82():284-9. PubMed ID: 10095448
[TBL] [Abstract][Full Text] [Related]
54. p53 and RB expression predict progression in T1 bladder cancer.
Grossman HB; Liebert M; Antelo M; Dinney CP; Hu SX; Palmer JL; Benedict WF
Clin Cancer Res; 1998 Apr; 4(4):829-34. PubMed ID: 9563875
[TBL] [Abstract][Full Text] [Related]
55. Differential expression of multiple MDM2 messenger RNAs and proteins in normal and tumorigenic breast epithelial cells.
Gudas JM; Nguyen H; Klein RC; Katayose D; Seth P; Cowan KH
Clin Cancer Res; 1995 Jan; 1(1):71-80. PubMed ID: 9815889
[TBL] [Abstract][Full Text] [Related]
56. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors.
Cordon-Cardo C; Zhang ZF; Dalbagni G; Drobnjak M; Charytonowicz E; Hu SX; Xu HJ; Reuter VE; Benedict WF
Cancer Res; 1997 Apr; 57(7):1217-21. PubMed ID: 9102201
[TBL] [Abstract][Full Text] [Related]
57. Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer.
Simon R; Struckmann K; Schraml P; Wagner U; Forster T; Moch H; Fijan A; Bruderer J; Wilber K; Mihatsch MJ; Gasser T; Sauter G
Oncogene; 2002 Apr; 21(16):2476-83. PubMed ID: 11971182
[TBL] [Abstract][Full Text] [Related]
58. Allelic deletions of cell growth regulators during progression of bladder cancer.
Primdahl H; von der Maase H; Christensen M; Wolf H; Orntoft TF
Cancer Res; 2000 Dec; 60(23):6623-9. PubMed ID: 11118045
[TBL] [Abstract][Full Text] [Related]
59. High prognostic significance of Mdm2/p53 co-overexpression in soft tissue sarcomas of the extremities.
Würl P; Meye A; Schmidt H; Lautenschläger C; Kalthoff H; Rath FW; Taubert H
Oncogene; 1998 Mar; 16(9):1183-5. PubMed ID: 9528860
[TBL] [Abstract][Full Text] [Related]
60. Analysis of Ki-ras, p53, and MDM2 genes in uterine leiomyomas and leiomyosarcomas.
Hall KL; Teneriello MG; Taylor RR; Lemon S; Ebina M; Linnoila RI; Norris JH; Park RC; Birrer MJ
Gynecol Oncol; 1997 May; 65(2):330-5. PubMed ID: 9159347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
